Healthcare Cost

Baffled by NAFLD: The Horse Might Be Out of the Barn but Should Not Take Us for a Ride

May 28th 2021, 1:00pm


As awareness of nonalcoholic fatty liver disease (NAFLD) rises, it is essential to develop and implement a rigorously determined approach to identify patients who will, or will not, benefit from diagnostic evaluation.

Population-Based Return on Investment of Deploying Transient Elastography

May 28th 2021, 1:00pm


Deploying vibration-controlled transient elastography/controlled attenuation parameter devices at the population level is a financially advantageous solution to address the epidemic of fatty liver disease.

Significant HCRU and Cost Burden for Patients With AML Who Relapse

May 26th 2021, 1:30pm


Patients with acute myeloid leukemia (AML) who relapse after first-line treatment face a substantial health care resource utilization (HCRU) and cost burden, according to a poster presented at Virtual ISPOR 2021.

The Economic Burden and Impact on HRQOL of Sickle Cell Disease

May 21st 2021, 6:52pm


Patients with sickle cell disease face substantial health care utilization and impaired health-related quality of life (HRQOL).

WHO Study Finds Long Working Hours May Increase Risk of Stroke, Heart Disease Mortality

May 21st 2021, 3:00pm


In 2016, long working hours were associated with 745,000 deaths and 23.3 million disability-adjusted life-years from ischemic heart disease and stroke combined.

Cost-effectiveness of Total State Coverage for Hepatitis C Medications

May 20th 2021, 1:00pm


Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.

Innovative Contracts Can Address the Value Elements of CGP in Cancer

May 20th 2021, 12:45pm


Stakeholders identify the value elements of comprehensive genomic profiling (CGP) they find most important, as well as options for innovative contracts.

US Health Plans Addressing Rising Drug Costs With Step Therapy, Value Assessment Frameworks

May 19th 2021, 10:00pm


As the cost of therapies increases, US health plans are utilizing tools like step therapy, to ensure patients try cheaper alternatives first, and value assessment frameworks, to assist with the decision-making process.

Mark Trusheim Speaks on ISPOR Payer Summit, Performance-Based Contracting

May 19th 2021, 9:28pm


Mark Trusheim, MS, BS, strategic director at the NEW Drug Development ParadIGmS program and visiting scientist at Massachusetts Institute of Technology, explains factors involved when considering whether a therapy would be suitable for performance-based contracting.

Gene Therapies Present Reimbursement Challenges That Have Yet to Be Answered

May 19th 2021, 6:55pm


With more than 3000 gene therapies in development, payers will have to grapple with the challenges of paying for these innovative but expensive therapies.